Myelodysplastic Syndrome With Autoimmune Disease: Clinical and Molecular Features and Survival Outcomes.
BACKGROUND: The myelodysplastic syndromes (MDS) frequently present with heterogeneous systemic inflammatory and autoimmune disease (AD). The MDS patients with AD+ demonstrated significantly higher overall survival (OS) (58.7% vs.
BACKGROUND: The myelodysplastic syndromes (MDS) frequently present with heterogeneous systemic inflammatory and autoimmune disease (AD). The MDS patients with AD+ demonstrated significantly higher overall survival (OS) (58.7% vs.
What the study was
- Study design
- Retrospective study
- Sample size
- 1456
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical lymphoma, myeloma & leukemia
Why it surfaced
Relevant Hematologic malignancies study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.